Update information

Minor changes since publication

November 2021: We updated recommendation 1.1 to say that treatment with talimogene laherparepvec is recommended only if systemically administered immunotherapies are not considered the best option by a multidisciplinary team. Previously the wording was if they were 'not suitable'.

ISBN: 978-1-4731-2088-4

  • National Institute for Health and Care Excellence (NICE)